Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228693 | 1.00 | MMP2 (0.44) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL7262682 | 0.96 | KEAP1 (0.43) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL1509783 | 0.73 | CYP2D6 (0.30) | — | |
| SCHEMBL8533151 | 0.71 | KEAP1 (0.47) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL8533154 | 0.69 | KEAP1 (0.47) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL29156174 | 0.67 | PKM (0.54) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL8276256 | 0.66 | MMP2 (0.58) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL13463174 | 0.65 | MMP2 (0.60) | MMP2MMP13KEAP1NFE2L2PKM | |
| SCHEMBL27042478 | 0.65 | ITGB3 (0.47) | MMP2MMP13PKMHDAC3HDAC4 | |
| SCHEMBL27042471 | 0.65 | ITGB3 (0.47) | MMP2MMP13PKMHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378066-B2 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | CORDEN PHARMA COLORADO, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090149628-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | ROCHE COLORADO CORPORATION | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149628-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | IAPP, GLP1R, INSR | MMP2 2874/4885MMP13 2215/4885KEAP1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.